Dr. Selina Laqui, MD, PhD
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Area of expertise
Oligoprogressive
Selina Laqui, MD, PhD has run 4 trials for Oligoprogressive. Some of their research focus areas include:
Prostate Cancer
Selina Laqui, MD, PhD has run 3 trials for Prostate Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of California Davis Comprehensive Cancer Center
University Of California, Davis
Clinical Trials Selina Laqui, MD, PhD is currently running
Loncastuximab Tesirine + Rituximab
for Diffuse Large B-Cell Lymphoma
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs such as doxorubicin, vincristine, and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving loncastuximab tesirine and rituximab in combination with dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone may be more effective at treating high risk diffuse large B-cell lymphoma patients than standard treatments.
Recruiting
1 award
Phase 2
Ablative Therapy
for Gastrointestinal Cancer
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Recruiting
1 award
N/A
14 criteria
More about Selina Laqui, MD, PhD
Clinical Trial Related
4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Selina Laqui, MD, PhD has experience with
- Cyclophosphamide
- Locally Ablative Therapy
- Venetoclax
- Locally Ablative Therapy
- Etoposide
- Rituximab
Breakdown of trials Selina Laqui, MD, PhD has run
Oligoprogressive
Prostate Cancer
Lymphoma
Biliary Tract Cancer
Double-hit lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Selina Laqui, MD, PhD specialize in?
Selina Laqui, MD, PhD focuses on Oligoprogressive and Prostate Cancer. In particular, much of their work with Oligoprogressive has involved Stage IV patients, or patients who are undergoing treatment.
Is Selina Laqui, MD, PhD currently recruiting for clinical trials?
Yes, Selina Laqui, MD, PhD is currently recruiting for 5 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Selina Laqui, MD, PhD has studied deeply?
Yes, Selina Laqui, MD, PhD has studied treatments such as Cyclophosphamide, Locally ablative therapy, Venetoclax.
What is the best way to schedule an appointment with Selina Laqui, MD, PhD?
Apply for one of the trials that Selina Laqui, MD, PhD is conducting.
What is the office address of Selina Laqui, MD, PhD?
The office of Selina Laqui, MD, PhD is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.